Democratic Republic of Congo vs Indonesia: Average cost of drugs for extensively drug-resistant tuberculosis
Democratic Republic of Congo
1,102 constant 2022 US$
in 2024
Indonesia
1,138 constant 2022 US$
in 2024
Democratic Republic of Congo rank
41st
Indonesia rank
40th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Democratic Republic of Congo
- Indonesia
How they compare
Indonesia currently reports 1,138 constant 2022 US$ against 1,102 constant 2022 US$ in Democratic Republic of Congo, a difference of 36 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2020 it was Democratic Republic of Congo ahead.
Democratic Republic of Congo ranks 41st and Indonesia ranks 40th of 56 countries.
Democratic Republic of Congo has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Democratic Republic of Congo or Indonesia?
- Indonesia, at 1,138 constant 2022 US$ against 1,102 constant 2022 US$ in Democratic Republic of Congo as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Democratic Republic of Congo and Indonesia?
- 36 constant 2022 US$, with Indonesia ahead.
- How many years of comparable data are there for Democratic Republic of Congo and Indonesia?
- 5 years are reported by both, from 2020 to 2024.
- How do Democratic Republic of Congo and Indonesia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Democratic Republic of Congo ranks 41st and Indonesia ranks 40th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.